|
1
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanders HR and Albitar M: Somatic
mutations of signaling genes in non-small-cell lung cancer. Cancer
Genet Cytogenet. 203:7–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Costa DB, Kobayashi S, Tenen DG and
Huberman MS: Pooled analysis of the prospective trials of gefitinib
monotherapy for EGFR-mutant non-small cell lung cancers. Lung
Cancer. 58:95–103. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Miller VA, Riely GJ, Zakowski MF, Li AR,
Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, et
al: Molecular characteristics of bronchioloalveolar carcinoma and
adenocarcinoma, bronchioloalveolar carcinoma subtype, predict
response to erlotinib. J Clin Oncol. 26:1472–1478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jackman DM, Miller VA, Cioffredi LA, Yeap
BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV and Johnson
BE: Impact of epidermal growth factor receptor and KRAS mutations
on clinical outcomes in previously untreated non-small cell lung
cancer patients: Results of an online tumor registry of clinical
trials. Clin Cancer Res. 15:5267–5273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li D, Zhang L, Zhou J and Chen H:
Cigarette smoke extract exposure induces EGFR-TKI resistance in
EGFR-mutated NSCLC via mediating Src activation and EMT. Lung
Cancer. 93:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pine SR, Marshall B and Varticovski L:
Lung cancer stem cells. Dis Markers. 24:257–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim CF, Jackson EL, Woolfenden AE,
Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT and Jacks T:
Identification of bronchioalveolar stem cells in normal lung and
lung cancer. Cell. 121:823–835. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak
J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang CP, Tsai MF, Chang TH, Tang WC, Chen
SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY and Lin SB:
ALDH-positive lung cancer stem cells confer resistance to epidermal
growth factor receptor tyrosine kinase inhibitors. Cancer Lett.
328:144–151. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leithner K, Hirschmugl B, Li Y, Tang B,
Papp R, Nagaraj C, Stacher E, Stiegler P, Lindenmann J, Olschewski
A, et al: TASK-1 regulates apoptosis and proliferation in a subset
of non-small cell lung cancers. PLoS One. 11:e01574532016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK,
Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al: Oct-4
expression maintained cancer stem-like properties in lung
cancer-derived CD133-positive cells. PLoS One. 3:e26372008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of Oct4 and nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kurrey NK, Jalgaonkar SP, Joglekar AV,
Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and slug
mediate radioresistance and chemoresistance by antagonizing
p53-mediated apoptosis and acquiring a stem-like phenotype in
ovarian Cancer cells. Stem Cells. 27:2059–2068. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Santisteban M, Reiman JM, Asiedu MK,
Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC,
Manjili MH, et al: Immune-induced epithelial to mesenchymal
transition in vivo generates breast cancer stem cells. Cancer Res.
69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tiran V, Stanzer S, Heitzer E, Meilinger
M, Rossmann C, Lax S, Tsybrovskyy O, Dandachi N and Balic M:
Genetic profiling of putative breast cancer stem cells from
malignant pleural effusions. PLoS One. 12:e01752232017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Demicheli R, Fornili M, Ambrogi F, Higgins
K, Boyd JA, Biganzoli E and Kelsey CR: Recurrence dynamics for
non-small-cell lung cancer: Effect of surgery on the development of
metastases. J Thorac Oncol. 7:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Senthi S, Lagerwaard FJ, Haasbeek CJ,
Slotman BJ and Senan S: Patterns of disease recurrence after
stereotactic ablative radiotherapy for early stage non-small-cell
lung cancer: A retrospective analysis. Lancet Oncol. 13:802–809.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sève P and Dumontet C: Chemoresistance in
non-small cell lung cancer. Curr Med Chem Anticancer Agents.
5:73–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lara PN Jr, Lau DH and Gandara DR:
Non-small-cell lung cancer progression after first-line
chemotherapy. Curr Treat Options Oncol. 3:53–58. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun S, Schiller JH and Gazdar AF: Lung
cancer in never smokers-a different disease. Nat Rev Cancer.
7:778–790. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brugger W and Thomas M: EGFR-TKI resistant
non-small cell lung cancer (NSCLC): New developments and
implications for future treatment. Lung Cancer. 77:2–8. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nurwidya F, Takahashi F, Murakami A,
Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N and Takahashi
K: Acquired resistance of non-small cell lung cancer to epidermal
growth factor receptor tyrosine kinase inhibitors. Respir Investig.
52:82–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wangari-Talbot J and Hopper-Borge E: Drug
resistance mechanisms in non-small cell lung carcinoma. J Can Res
Updates. 2:265–282. 2013.PubMed/NCBI
|
|
34
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou BB, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Wakeman TP, Lathia JD, Hjelmeland
AB, Wang XF, White RR, Rich JN and Sullenger BA: Notch promotes
radioresistance of glioma stem cells. Stem Cells. 28:17–28.
2010.PubMed/NCBI
|
|
38
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie M, Zhang L, He CS, Xu F, Liu JL, Hu
ZH, Zhao LP and Tian Y: Activation of notch-1 enhances
epithelial-mesenchymal transition in gefitinib-acquired resistant
lung cancer cells. J Cell Biochem. 113:1501–1513. 2012.PubMed/NCBI
|
|
40
|
Hirvonen R, Talvensaari-Mattila A, Pääkkö
P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) in
T(1–2)N0 breast carcinoma. Breast Cancer Res Treat. 77:85–91. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kalhori V and Törnquist K: MMP2 and MMP9
participate in S1P-induced invasion of follicular ML-1 thyroid
cancer cells. Mol Cell Endocrinol. 404:113–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu B, Cui J, Sun J, Li J, Han X, Guo J,
Yi M, Amizuka N, Xu X and Li M: Immunolocalization of MMP9 and MMP2
in osteolytic metastasis originating from MDA-MB-231 human breast
cancer cells. Mol Med Rep. 14:1099–1106. 2016. View Article : Google Scholar : PubMed/NCBI
|
